Table 2. Visual acuity change from baseline at one year by the number of minor alleles in VEGFR2 SNPs rs4576072 and rs6828477 in CATT and IVAN.
| Ranibizumab and Bevacizumab Combined | Ranibizumab Only | |||
|---|---|---|---|---|
| Number of minor (C) alleles | n (%) | Letters Mean (SD) | n (%) | Letters Mean (SD) |
| CATT | ||||
| 0 | 183 (22) | 9.3 (14.2) | 97 (22) | 10.9 (10.9) |
| 1 | 387 (46) | 8.0 (14.2) | 193 (45) | 8.7 (12.8) |
| 2 | 207 (25) | 7.9 (14.2) | 120 (28) | 8.5 (13.4) |
| 3 | 56 (7) | 7.2 (14.2) | 22 (5) | 5.6 (15.2) |
| 4 | 2 (0) | 0.0 (0.0) | 0 (0) | -- |
| Linear Trend P | 0.24 | 0.07 | ||
| IVAN | ||||
| 0 | 133 (26) | 5.3 (11.2) | 69 (26) | 5.0 (10.9) |
| 1 | 196 (39) | 6.3 (12.6) | 106 (40) | 6.2 (12.5) |
| 2 | 145 (29) | 5.3 (12.1) | 75 (28) | 7.8 (13.6) |
| 3 | 26 (5) | 3.7 (10.8) | 15 (6) | 5.1 (4.4) |
| 4 | 7 (1) | 5.7 (22.5) | 3 (1) | 19.7 (17.8) |
| Linear Trend P | 0.72 | 0.13 | ||
SD = Standard deviation.
CATT = Comparison of AMD Treatments Trials.
IVAN = Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularization.